Venlafaxine vs Duloxetine

Both medications are effective for major depressive disorder, with response rates of 50–65% ^[1][2]. The 2018 Cipriani meta-analysis found venlafaxine slightly more efficacious than duloxetine for depression, though the difference was modest ^[3]. For anxiety, venlafaxine has FDA approval for generalized anxiety disorder, social anxiety disorder, and panic disorder ^[1]. Duloxetine is approved for generalized anxiety disorder ^[2]. Where they diverge most significantly is pain: duloxetine has FDA approval for diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain (including osteoarthritis and chronic low back pain), making it the SNRI of choice when depression or anxiety coexists with chronic pain ^[2]. The OPTION-DM trial confirmed duloxetine's efficacy for painful diabetic neuropathy ^[4]. Venlafaxine has less robust evidence for pain, though it is used off-label for neuropathic pain and migraine prophylaxis. For stress urinary incontinence, duloxetine is approved in some countries (not the US) and is used off-label ^[2].

Both drugs share core SNRI side effects: nausea (20–30%), headache, dizziness, dry mouth, insomnia, and sexual dysfunction (30–40%) ^[1][2]. However, important differences exist. Venlafaxine causes dose-dependent hypertension in 10–13% of patients at doses above 225 mg/day, necessitating blood pressure monitoring ^[1]. Duloxetine has minimal blood pressure effects. Venlafaxine has one of the most severe discontinuation syndromes of any antidepressant — brain zaps, severe dizziness, irritability, and flu-like symptoms — due to its short half-life ^[3]. Duloxetine also causes discontinuation symptoms, but they are generally less severe. Duloxetine carries a specific risk of hepatotoxicity and is contraindicated in patients with chronic liver disease or substantial alcohol use ^[2]. It should not be used with thioridazine or MAOIs. Duloxetine is a moderate CYP2D6 inhibitor, creating more drug interaction potential than venlafaxine ^[4]. Sweating (10–14%) and constipation are more common with venlafaxine. Weight gain is possible with both but is generally modest (1–3 kg).

Both are available as generics at affordable prices. Generic venlafaxine ER 75 mg (30 capsules) costs $8–20 ^[1]. Generic duloxetine 60 mg (30 capsules) costs $8–20 ^[2]. Brand-name Effexor XR costs $250–400/month and Cymbalta costs $300–450/month, but both are rarely prescribed given generic availability. Both are covered by most insurance plans at the lowest copay tier. For patients with chronic pain conditions, duloxetine may represent better value by treating both mood and pain with a single medication, potentially reducing the need for additional pain prescriptions.

Both are typically taken once daily. Venlafaxine ER is taken in the morning with food at doses of 75–225 mg/day (maximum 375 mg/day) ^[1]. Duloxetine is taken once daily (some patients split to twice daily for GI tolerability) at 60 mg/day for depression and 60–120 mg/day for pain conditions ^[2]. Duloxetine capsules should be swallowed whole — they cannot be opened, crushed, or chewed due to enteric coating ^[2]. Venlafaxine ER capsules can be opened and sprinkled on applesauce. Tapering is essential for both medications but is more challenging with venlafaxine — reductions should be no more than 37.5 mg per week, and some patients require even slower tapers using bead-counting methods ^[3]. Duloxetine tapering is more straightforward, typically reducing from 60 mg to 30 mg for 1–2 weeks before stopping. Neither requires routine laboratory monitoring, though liver function tests are recommended before starting duloxetine ^[4].

Duloxetine is the preferred choice when depression or anxiety coexists with chronic pain conditions (diabetic neuropathy, fibromyalgia, chronic musculoskeletal pain), as it has robust FDA-approved indications for these conditions ^[2]. It is also preferred for patients concerned about discontinuation difficulty and those without liver disease. Venlafaxine may be preferred when maximum antidepressant efficacy is the primary goal (slight advantage in meta-analyses), for panic disorder (FDA indication duloxetine lacks), for migraine prophylaxis (more evidence), or when the clinician wants dose-dependent norepinephrine flexibility ^[1][3]. Venlafaxine should be avoided in uncontrolled hypertension, and duloxetine should be avoided in patients with liver disease or heavy alcohol use. Both are reasonable second-line antidepressants after SSRI failure. Consult your healthcare provider to choose the SNRI that best matches your symptom profile and comorbidities.